Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

OCEA Ocean Biomedical Inc

0,5582

-0,0418 (-6,97%)

01 Jan 2025 - Fermé

Retardé de 15 minutes

Form EFFECT - Notice of Effectiveness

Ocean Biomedical (NASDAQ:OCEA)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Plus de graphiques de la Bourse Ocean Biomedical

Ocean Biomedical (NASDAQ:OCEA)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025

Plus de graphiques de la Bourse Ocean Biomedical

Actualités Ocean Biomedical Inc

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Vendredi 22 Novembre 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
Mardi 22 Octobre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Mardi 1 Octobre 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
Mardi 27 Août 2024 ( il y a 4 mois) • GlobeNewswire Inc.

Form 8-K - Current report
Vendredi 23 Août 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Vendredi 23 Août 2024 ( il y a 4 mois) • GlobeNewswire Inc.

Form 8-K - Current report
Mardi 23 Juillet 2024 ( il y a 5 mois) • Edgar (US Regulatory)

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
Mercredi 5 Juin 2024 ( il y a 7 mois) • GlobeNewswire Inc.

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Jeudi 30 Mai 2024 ( il y a 7 mois) • GlobeNewswire Inc.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
Jeudi 16 Mai 2024 ( il y a 8 mois) • GlobeNewswire Inc.

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
Mercredi 24 Avril 2024 ( il y a 8 mois) • GlobeNewswire Inc.

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
Jeudi 28 Mars 2024 ( il y a 9 mois) • GlobeNewswire Inc.

Plus d'articles sur Ocean Biomedical Inc

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales